mk 0663 has been researched along with Ectopic Ossification in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brinkhoff, F; Krapp, J; Nottenkämper, J; Oberberg, S; Willburger, RE | 1 |
| Heukamp, M; Krapp, J; Nottenkämper, J; Oberberg, S; Willburger, RE | 1 |
| Barta, S; Craiovan, B; Grifka, J; Handel, M; Kehl, V; Springorum, HR; Vaitl, T; Winkler, S | 1 |
| Brunnekreef, JJ; Hoogervorst, P; Ploegmakers, MJ; Rijnen, WH; Schreurs, BW | 1 |
2 trial(s) available for mk 0663 and Ectopic Ossification
| Article | Year |
|---|---|
Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Humans; Incidence; Male; Middle Aged; Ossification, Heterotopic; Pelvis; Perioperative Period; Prospective Studies; Pyridines; Sulfones | 2016 |
Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Etoricoxib; Female; Hip Joint; Hip Prosthesis; Humans; Male; Middle Aged; Ossification, Heterotopic; Osteoarthritis, Hip; Prospective Studies; Pyridines; Radiography; Severity of Illness Index; Sulfones; Treatment Outcome | 2013 |
2 other study(ies) available for mk 0663 and Ectopic Ossification
| Article | Year |
|---|---|
Heterotopic ossification after total hip arthroplasty: When is development completed?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Ossification, Heterotopic; Postoperative Complications; Prospective Studies | 2022 |
Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ossification, Heterotopic; Treatment Outcome | 2021 |